Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 0.69 |
| ▸ | PTH1R | Q03431 | 9/20 | 0.67 |
| ▸ | GLP1R | P43220 | 6/20 | 0.65 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.65 |
| ▸ | GCGR | P47871 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29922398 | 0.94 | GLP1R (0.69) | KEAP1PTH1RGLP1RRXFP1GCGR | |
| SCHEMBL29391164 | 0.94 | GLP1R (0.65) | KEAP1PTH1RGLP1RRXFP1 | |
| SCHEMBL28972123 | 0.93 | KEAP1 (0.69) | KEAP1GLP1RGCGR | |
| SCHEMBL30536952 | 0.92 | GLP1R (0.70) | PTH1RGLP1RGCGR | |
| Cecropin A SCHEMBL29361111 | 0.92 | KEAP1 (0.67) | KEAP1GLP1RGCGR | |
| SCHEMBL30874225 | 0.92 | GLP1R (0.73) | PTH1RGLP1RGCGR | |
| SCHEMBL31759052 | 0.91 | GLP1R (0.75) | PTH1RGLP1RGCGR | |
| SCHEMBL30804686 | 0.91 | TFPI (0.58) | KEAP1PTH1RGLP1R | |
| SCHEMBL30029149 | 0.91 | GLP1R (0.68) | PTH1RGLP1RGCGR | |
| SCHEMBL30029354 | 0.91 | GLP1R (0.68) | PTH1RGLP1RGCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1601 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026101236-A1 | PEPTIDES SPECIFICALLY BINDING TO CCR8, AND USE THEREOF | 경희대학교 산학협력단 | 2026-05-15 | — | — | WO | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-12560607-B2 | Recombinant viruses, insect cells and their uses in viral detection and vaccination | ACADEMIA SINICA (TW) | 2026-02-24 | — | — | US | claimed |
| EP-4677075-A2 | TARGETING CELLS IN STRESSED GROWING CONDITIONS | SNIPR Biome ApS (DK) | 2026-01-14 | — | — | EP | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| US-20260000782-A1 | ITGB2-MEDIATED DRUG DELIVERY SYSTEM | TWINPIG BIOLAB INC. (KR) | 2026-01-01 | — | — | US | claimed |
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| US-20250228951-A1 | NOVEL-PEPTIDE-BASED ANTICANCER IMMUNOTHERAPEUTIC AGENT | TWINPIG BIOLAB INC. (KR) | 2025-07-17 | — | — | US | claimed |
| CN-112689758-B | Device and method for checking the effect of a drug on microorganisms | 上海宜晟生物科技有限公司 | 2025-03-28 | — | — | CN | claimed |
| CN-118599879-B | Homologous recombination bacillus subtilis for expressing cecropin B gene and construction method thereof | 长江大学 | 2025-03-04 | — | — | CN | claimed |
| CN-115838409-A | Preparation method and application of pH-responsive Cecropin B antibacterial polypeptide | 武汉理工大学 | 2023-03-24 | — | — | CN | claimed |
| EP-4103585-A1 | PEPTIDES TARGETING MACROPHAGES, AND CONJUGATES, COMPOSITIONS, AND USES THEREOF | Twinpig Biolab, Inc. (KR) | 2022-12-21 | — | — | EP | claimed |
| US-20220354957-A1 | PEPTIDES TARGETING MACROPHAGES, AND CONJUGATES, COMPOSITIONS, AND USES THEREOF | TWINPIG BIOLAB, INC. (KR) | 2022-11-10 | — | — | US | claimed |
| WO-2022234346-A1 | PEPTIDES TARGETING MACROPHAGES, AND CONJUGATES, COMPOSITIONS, AND USES THEREOF | TWINPIG BIOLAB, INC. (KR) | 2022-11-10 | — | — | WO | claimed |
| US-11484601-B2 | Targeting M2-like tumor-associated macrophages by using melittin-based proapoptotic peptide | TWINPIGBIOLAB INC. (KR) | 2022-11-01 | — | — | US | claimed |
| CN-115057943-A | Antibacterial peptide fusion protein and preparation method and application thereof | 杭州水芭莎生物医药科技有限公司 | 2022-09-16 | — | — | CN | claimed |
| CN-114904402-A | Layer-by-layer self-assembled slow-release antibacterial polymer separation membrane and preparation method and application thereof | 东华大学 | 2022-08-16 | — | — | CN | claimed |
| US-11345956-B2 | Methods and compositions related to prostate cancer therapeutics | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-05-31 | — | — | US | claimed |
| WO-2022079220-A2 | FLMG-DEPENDENT SOLUBLE PROTEIN O-GLYCOSYLATION SYSTEMS IN BACTERIA | UNIVERSITÉ DE GENÈVE (CH) | 2022-04-21 | — | — | WO | claimed |
| CN-109387641-B | Device and method for detecting cecropin B by using magnetic iron oxide nanoparticles as signal amplifier | 深圳职业技术学院 | 2022-04-15 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | HDAC3, HDAC1, HDAC4 | KEAP1 1995/4885PTH1R 4585/4885GLP1R 3640/4885 |
| US-12560607-B2 | Recombinant viruses, insect cells and their uses in viral detection and vaccination | HSPB1, HSPA2, HSPBP1 | KEAP1 2969/4885PTH1R 945/4885GLP1R 693/4885 |
| US-20260000782-A1 | ITGB2-MEDIATED DRUG DELIVERY SYSTEM | ITGB8, ITGB2, ITGA8 | KEAP1 4549/4885PTH1R 2619/4885GLP1R 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.